Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

Leukemia. 2009 May;23(5):994-7. doi: 10.1038/leu.2008.356. Epub 2008 Dec 18.

Authors

K Vandyke, A L Dewar, A N Farrugia, S Fitter, L Bik To, T P Hughes, A C W Zannettino

PMID: 19092851
DOI: 10.1038/leu.2008.356

No abstract available

Publication types

Letter

MeSH terms

Animals
Bone Marrow / drug effects
Cell Proliferation / drug effects
Cells, Cultured
Dasatinib
HSP90 Heat-Shock Proteins / metabolism
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Macrophages / cytology
Macrophages / drug effects
Mice
Myeloid Cells / drug effects
Osteoclasts / drug effects*
Phosphorylation / drug effects
Protein Kinase Inhibitors / pharmacology*
Pyrimidines / pharmacology*
Receptor, Macrophage Colony-Stimulating Factor / metabolism
Thiazoles / pharmacology*
src-Family Kinases / metabolism

Substances

HSP90 Heat-Shock Proteins
Protein Kinase Inhibitors
Pyrimidines
Thiazoles
Receptor, Macrophage Colony-Stimulating Factor
src-Family Kinases
Dasatinib